Drug Makers’ Shares Hit ‘All-Time High’ Off Of Price-Gouging American Patients Today Big Pharma giant Novartis announced better-than-expected earnings for the second quarter of 2019. The brand name drug maker reported $11.76 billion in sales in Q2 – up from $11.34 billion last year – beating analysts’ expectations. As a result, the company raised its […]
Drug Maker Bests Q2 Forecasts After Hiking Prices on Dozens of Drugs in 2019 It’s that time again. Pharmaceutical companies are starting to report their earnings for Q2. Big Pharma giant Johnson & Johnson out of the gate Tuesday. The brand name drug maker announced better-than-expected second quarter earnings and raised its sales forecast for […]
Greater List Price Transparency Will Help Hold Big Pharma Accountable, Deter Price-Gouging Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today encouraging the U.S. House Committee on Energy & Commerce to advance the FAIR Drug Pricing Act being considered in a markup of over two dozen bills by the full […]
Drug Makers Continue Price-Gouging Patients as Americans Demand Accountability The summer is heating up and so too is Big Pharma’s zeal for putting profits over people. Brand name drug makers kicked off the mid-year months with price hikes on hundreds of drugs. Big Pharma’s summer price-gouging bonanza builds on the industry’s rapid pace of price […]
America’s seniors and taxpayers received a huge win today when the administration made the right call to withdraw a proposal, known as the Rebate Rule, from the Department of Health and Human Services (HHS). The Campaign for Sustainable Rx Pricing (CSRxP) was a leading voice raising concerns with the proposed rule, including, among others, its […]
Decision to Sideline Misguided Proposal a Huge Win for America’s Seniors & Taxpayers, Loss for Big Pharma Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today reacting to the administration’s decision to withdraw a proposal from the Department of Health and Human Services (HHS) known as the Rebate Rule. “This decision […]
Proposed Bill Would Undermine Fair and Efficient Review Process Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today on the introduction of The Support Technology & Research for Our Nation’s Growth and Economic Resilience (STRONGER) Patents Act of 2019. “Inter partes reviews (IPR) were established by Congress through the America […]
Lauren Aronson The Hill July 9, 2019 The American people are demanding that Congress hold Big Pharma accountable and the momentum to lower prescription drug prices has never been greater. For years we’ve seen outrageous examples of price-gouging. The price of a drug that treats opioid overdose increased by more than 550 percent in three […]
Senators Advance Three Measures to Help Lower Drug Prices as Momentum to Hold Drug Makers Accountable Builds Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement praising lawmakers on the U.S. Senate Committee on the Judiciary for advancing three important measures to crack down on anti-competitive tactics employed by Big […]
Advancement of CREATES and FAIR Drug Pricing Acts Marks Step Toward Boosting Competition and Transparency Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement praising lawmakers on the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee for taking up and advancing two bipartisan measures to boost competition and increase […]